BeOne Medicines Ltd.
ONCNASDAQHealthcare● Active
$270.10
$-9.83(-3.51%)
Market Cap$28.9B
P/E Ratio—
52W High$385.22
52W Low$239.25
BeOne Medicines Ltd. (ONC) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ONC · earnings · updated Jun 8, 2026
Latest Earnings
Q2 FY2026Report Date: May 6, 2026EPS Actual
$1.96
Est. $0.73 · +168.5%
Revenue
$1.51B
Est. $1.48B · +2.5%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 6, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 1-Quarter EPS Beat Streak
ONC reports quarterly as a NASDAQ-listed Medical - Pharmaceuticals company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
85
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $0.84B
Days Away85
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$0.84B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | $1.65 | — | — | — | $1.59B | — |
| ▲ Q2 FY2026 | May 6, 2026 | $0.73 | $1.96 | +168.5% | $1.51B | $1.48B | +2.5% |
| ▼ Q1 FY2026 | Feb 26, 2026 | $1.60 | $0.58 | -63.8% | $1.50B | $1.47B | +2.2% |
| ▲ Q4 FY2025 | Nov 6, 2025 | $0.72 | $1.09 | +51.4% | $1.41B | $1.45B | -2.7% |
| ▲ Q3 FY2025 | Aug 6, 2025 | $0.48 | $0.84 | +75.0% | $1.32B | $1.44B | -8.8% |
| ▲ Q2 FY2025 | May 7, 2025 | -$0.71 | $1.22 | +271.8% | $1.12B | $1.25B | -10.4% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -$0.88 | -$1.43 | -62.5% | $1.13B | $1.04B | +8.5% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -$0.88 | -$1.15 | -30.7% | $1.00B | — | — |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
$1.65
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 6, 2026Beat
EPS Actual
$1.96
EPS Est.
$0.73
EPS Surpr.
+168.5%
Revenue
$1.51B
Q1 FY2026
Feb 26, 2026Miss
EPS Actual
$0.58
EPS Est.
$1.60
EPS Surpr.
-63.8%
Revenue
$1.50B
Q4 FY2025
Nov 6, 2025Beat
EPS Actual
$1.09
EPS Est.
$0.72
EPS Surpr.
+51.4%
Revenue
$1.41B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
$0.84
EPS Est.
$0.48
EPS Surpr.
+75.0%
Revenue
$1.32B
Q2 FY2025
May 7, 2025Beat
EPS Actual
$1.22
EPS Est.
-$0.71
EPS Surpr.
+271.8%
Revenue
$1.12B
Q1 FY2025
Feb 27, 2025Miss
EPS Actual
-$1.43
EPS Est.
-$0.88
EPS Surpr.
-62.5%
Revenue
$1.13B
Q4 FY2024
Nov 12, 2024Miss
EPS Actual
-$1.15
EPS Est.
-$0.88
EPS Surpr.
-30.7%
Revenue
$1.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $6.13 | $6.46 | $6.85 | 3 |
| Q3 FY2028 | $2.16 | $2.27 | $2.41 | 3 |
| Q2 FY2028 | $2.11 | $2.22 | $2.36 | 3 |
| Q1 FY2028 | $1.95 | $2.06 | $2.19 | 3 |
| Q4 FY2027 | $3.07 | $3.24 | $3.44 | 2 |
| Q3 FY2027 | $2.35 | $2.48 | $2.63 | 2 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2028 | $2.4B | $2.5B | $2.6B | 6 |
| Q3 FY2028 | $1.7B | $1.7B | $1.8B | 3 |
| Q2 FY2028 | $1.6B | $1.7B | $1.8B | 5 |
| Q1 FY2028 | $1.5B | $1.6B | $1.7B | 3 |
| Q4 FY2027 | $1.9B | $1.9B | $2.0B | 7 |
| Q3 FY2027 | $1.8B | $1.8B | $1.9B | 4 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 6, 2026 | +168.5% | $297.49 | $313.32 | +5.32% |
| ▼ Q1 FY2026 | Feb 26, 2026 | -63.8% | $352.23 | $322.37 | -8.48% |
| ▲ Q4 FY2025 | Nov 6, 2025 | +51.4% | $321.39 | $332.36 | +3.41% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +75.0% | $307.23 | $298.52 | -2.84% |
| ▲ Q2 FY2025 | May 7, 2025 | +271.8% | $241.75 | $232.25 | -3.93% |
| ▼ Q1 FY2025 | Feb 27, 2025 | -62.5% | $259.00 | $278.38 | +7.48% |
| ▼ Q4 FY2024 | Nov 12, 2024 | -30.7% | $205.04 | $193.64 | -5.56% |
| ▲ Q3 FY2024 | Aug 7, 2024 | +45.2% | $171.32 | $176.73 | +3.16% |
Q2 FY2026+5.32%
Report Date
May 6, 2026
EPS Beat/Miss
+168.5%
Price Before
$297.49
Price After
$313.32
Q1 FY2026-8.48%
Report Date
Feb 26, 2026
EPS Beat/Miss
-63.8%
Price Before
$352.23
Price After
$322.37
Q4 FY2025+3.41%
Report Date
Nov 6, 2025
EPS Beat/Miss
+51.4%
Price Before
$321.39
Price After
$332.36
Q3 FY2025-2.84%
Report Date
Aug 6, 2025
EPS Beat/Miss
+75.0%
Price Before
$307.23
Price After
$298.52
Q2 FY2025-3.93%
Report Date
May 7, 2025
EPS Beat/Miss
+271.8%
Price Before
$241.75
Price After
$232.25
Q1 FY2025+7.48%
Report Date
Feb 27, 2025
EPS Beat/Miss
-62.5%
Price Before
$259.00
Price After
$278.38
Q4 FY2024-5.56%
Report Date
Nov 12, 2024
EPS Beat/Miss
-30.7%
Price Before
$205.04
Price After
$193.64
Q3 FY2024+3.16%
Report Date
Aug 7, 2024
EPS Beat/Miss
+45.2%
Price Before
$171.32
Price After
$176.73
Avg Beat Reaction+1.02%
Avg Miss Reaction-2.19%
Beat Rate5 / 8 quarters
Largest Move-8.48% (Q1 FY2026)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ONC ends December
BeOne Medicines Ltd. (ONC) most recently reported earnings on May 6, 2026 for Q2 FY2026, posting EPS of $1.96 — beating the analyst consensus of $0.73 by +168.5%. The next ONC earnings date is expected around September 1, 2026.
Each quarter, investors track ONC earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ONC revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ONC's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ONC earnings · 5 questionsBeOne Medicines Ltd.'s next earnings report is expected around September 1, 2026. ONC typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ONC historically reports after market close (AMC).
ONC earnings datewhen is ONC earningsONC next earnings datewhen does ONC report earningsONC earnings calendar
▸ Source: FMP · BeOne Medicines Ltd. SEC filings · US GAAP · BeOne Medicines Ltd. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026